Go Deep
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,739 | -9.6 | 3.29 | 0.02 | 2,760.82 |
| Oct 2026 | 19,839 | -9.3 | 3.21 | 0.02 | 2,689.86 |
| Oct 2026 | 19,651 | -10.0 | 3.35 | 0.02 | 2,808.00 |
| Oct 2026 | 19,954 | -9.1 | 3.13 | 0.02 | 2,611.29 |
| Oct 2026 | 19,798 | -9.4 | 3.24 | 0.02 | 2,711.75 |
| Oct 2026 | 19,682 | -9.7 | 3.33 | 0.02 | 2,784.76 |
| Oct 2026 | 20,335 | -8.3 | 2.84 | 0.02 | 2,370.23 |
| Oct 2026 | 20,112 | -8.8 | 3.01 | 0.02 | 2,504.19 |
Rapport Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 20,000,000.0 | 0.0 | 0.0 |
| Net Profit | -56,615,000.0 | -19,857,000.0 | -33,763,000.0 | -26,925,000.0 |
| EPS | -1.2 | -0.4 | -0.7 | -0.7 |
Rapport Therapeutics, Inc. Revenue & Profit: Last 3 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| Net Profit | -111,483,000.0 | -78,307,000.0 | -34,786,000.0 |
| EPS | -2.9 | -3.8 | -23.1 |
Rapport Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 512,431,000.0 | 314,933,000.0 | 155,423,000.0 | 31,603,000.0 |
| Total Liabilities | 27,778,000.0 | 9,506,000.0 | 181,057,000.0 | 41,665,000.0 |
| Total Equity | 484,653,000.0 | 305,427,000.0 | -25,634,000.0 | -10,062,000.0 |
Owes vs Owns
Rapport Therapeutics, Inc. owed $0.08 for every $1 it owned in Jun 2026, down from $1.32 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.08× | 0.05× | 0.03× | 1.16× | 1.32× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Rapport Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.7%Fixed assets (tangible) 2.5%Other assets 1.8%
How it's funded — Dec 2025
Short-term debt 0.5%Long-term debt 1.7%Payables 0.8%Other liabilities 2.4%Shareholders' equity 94.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 490.5 | 305.3 | 147.5 | 31.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 12.9 | 5.0 | 4.0 | 0.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.0 | 4.7 | 3.9 | 0.1 |
| Liabilities & equity | ||||
| Short-term debt | 2.8 | 0.7 | 0.7 | 0.0 |
| Long-term debt | 8.7 | 0.7 | 1.5 | 0.0 |
| Payables | 4.2 | 2.0 | 2.5 | 1.4 |
| Other liabilities | 12.1 | 6.1 | 176.4 | 40.2 |
| Shareholders' equity | 484.7 | 305.4 | -25.6 | -10.1 |
| Net tangible assets | 484.7 | 305.4 | -25.6 | -10.1 |
Rapport Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Operating Activities | -87,473,000.0 | -64,828,000.0 | -27,181,000.0 |
| Investing Activities | -187,473,000.0 | -170,141,000.0 | -78,860,000.0 |
| Financing Activities | 270,786,000.0 | 221,625,000.0 | 145,136,000.0 |